The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...
The FDA has approved an oral combination therapy for certain adults with newly diagnosed acute myeloid leukemia.Decitabine ...
Long-term survivors demonstrated clinically meaningful decrements in SF-36 physical functioning and role-physical scores versus general population norms, indicating persistent limitations in daily ...
On May 13, the Food and Drug Administration (FDA) approved decitabine and cedazuridine (Inqovi) tablets in combination with ...
The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies. Management of newly diagnosed acute ...
A patient received a dose of the novel menin inhibitor, ziftomenib, plus Xospata in a phase 1 trial for patients with AML. While posttransplant Xospata did not worsen quality of life in patients with ...
A limitation to cancer treatment, specifically acute myeloid leukemia (AML) is the ability to effectively target tumors cells ...
FDA cleared oral decitabine/cedazuridine plus venetoclax for frontline AML in adults ≥75 years or with comorbidities that make intensive induction inappropriate. Study ASTX727-07 (single-arm, ...
The incidence of therapy-related acute myeloid leukemia almost tripled over 30 years, according to a study from Japan. Rising rates paradoxically reflect medical success, as more patients are living ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results